The Psychedelic Podcast

Paul F. Austin and Tobias Erny explore low-dose ibogaine for Parkinson's disease: a published case report, GDNF, who responds, and drug safety. Find full show notes and links here: https://thethirdwave.co/podcast/episode-378/?ref=250 In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Tobias Erny, a Swiss iboga practitioner, researcher, and Co-Director of the Global Iboga Therapy Alliance. Tobias shares how ibogaine helped him end his own opiate addiction, and how that recovery grew into two decades of work with iboga, including a published case report on low-dose ibogaine for Parkinson's disease. Paul and Tobias explore why ibogaine may help some people living with Parkinson's, from GDNF, a growth factor that supports dopamine neurons, to its effects on mood and motivation. They also discuss how ibogaine differs from the whole iboga plant, why many patients don't respond, the medication interactions families should understand first, and why starting low and staying honest about uncertainty matters as research moves toward a clinical trial. Episode Links: Tobias Erny on LinkedIn Ibogaine and Parkinson's disease case report, Journal of Psychedelic Studies Talk with before and after video of a Parkinson's patient Episode Sponsors: The Microdosing Practitioner Certification at Psychedelic Coaching Institute. Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Eiad Asbahi, founder of Mindscape, a patient care coordination platform that connects people with licensed providers and pharmacies for low-dose ketamine care. Eiad spent 17 years running a hedge fund and reached the kind of success he had always dreamed about. Then his largest investment collapsed and his marriage ended, and he was forced to look inward. This epsiode is sponsored by Eiad Asbahi. Eiad describes the moment he realized he was the common denominator in his own failures. He talks about the core belief underneath it all, that he was "defective," and how Internal Family Systems therapy showed him there are no bad parts. He explains how building inner safety changed the way he parents his daughter, and why he uses ketamine to reconnect rather than to escape. Paul and Eiad also discuss the thinking behind Mindscape's daily low-dose model and the case for repetition over peak experiences. The conversation ends with a candid disagreement about dependence, personal agency, clinical oversight, and what responsible access to ketamine should look like. Eiad Asbahi is a founder and father. He spent 17 years running a hedge fund and reached the highest levels of professional success before a long professional collapse. Around the same time, a divorce sent him inward. He wanted to model a secure relationship for his daughter, so he began Internal Family Systems therapy and spent the next five years rebuilding his relationship with himself. Eiad founded Mindscape to make the kind of guided, medically supervised care that changed his life easier to find and navigate. Mindscape is a patient care coordination platform that connects people with independently licensed providers and pharmacies, and its approach is built on repetition over intensity. Today his work centers on what comes after healing: deliberately rebuilding identity, motivation, and meaning. Highlights: From hedge fund highs to a five-year professional collapse Realizing he was the common denominator in his failures The core belief beneath it all: feeling defective Internal Family Systems and the idea that there are no bad parts How repeated inner work builds inner safety Becoming the protector for his daughter that he never had How Mindscape's stripped-down model differs from other ketamine platforms Daily low-dose ketamine: repetition over intensity, connection over escape Eiad's self-care practices: movement, music, and red light Dependence, agency, and accountability: where Paul and Eiad disagree Episode Links: Mindscape: https://themindscape.com/ Mindscape on Instagram: https://www.instagram.com/themindscape.official Eiad on Instagram: https://www.instagram.com/eiadasbahi

In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Mira Funk, LCSW, a Harvard-educated psychotherapist and the founder of Unjourneying, a private practice built around 5-MeO-DMT, N,N-DMT, and salvia divinorum. This episode is sponsored by Mira Funk. Mira traces her path from fourteen years of Zen meditation into psychedelic work, and explains how a severe reaction to a common nootropic supplement unexpectedly reoriented her entire practice toward presence rather than dramatic, otherworldly trips. She and Paul go deep on the extended-release routes she has pioneered, including subcutaneous, rectal, and vaginal 5-MeO-DMT, and the titrated e-mesh method she uses for salvia divinorum. Throughout the conversation, Mira is candid about the real risks of self-administration, the role of chronic illness in shaping her gentle approach, and why she believes structure matters most for those newest to this work. Mira Funk, LCSW (she/her), is a Harvard-educated queer, nonbinary psychotherapist and psychedelic guide specialized in 5-MeO-DMT, N,N-DMT (including analog ayahuasca), and salvia divinorum. Based in Oregon, she is the founder of Unjourneying, a private therapy practice blending somatic, nondual, and neuroscience-informed methods to optimize psychedelic healing and insight. Unjourneying draws its name from Neem Karoli Baba's reported non-response to LSD; observing this same effect in herself and long-term clients, Mira embraced the radically vivid here and now as her lodestar, rather than some mystical elsewhere. Having battled neurological Lyme disease for over three decades, Mira brings a gentle, trauma-informed approach to clients with physical and emotional challenges. She is the inventor of The Hourglass, a lung-friendly 5-MeO-DMT vaporization system with zero liquid carriers and two-stage cooling, and offers multiple extended-release routes of 5-MeO-DMT, including subcutaneous, rectal, and vaginal preparations for sexual trauma and pelvic floor dysfunction. She is currently the only psychedelic therapist in the field offering titrated dosing of pure salvinorin-A in an e-mesh format. Highlights: Fourteen years of Zen before mushrooms filled the gap Why structure helps most early in psychedelic work A supplement reaction that reshaped her entire practice 5-MeO-DMT as explosion versus something you can surf Building The Hourglass: her own zero-liquid vaporizer Subcutaneous, rectal & vaginal routes for 5-MeO-DMT A rectal 5-MeO-DMT session and healing pelvic trauma Real risks of DIY dosing and sourcing injectables safely Titrating salvia to a whisper with a custom e-mesh device Episode Links: Unjourneying (Mira's website): https://www.unjourneying.com/ Mira on Instagram: https://www.instagram.com/unjourneying YouTube: https://www.youtube.com/@unjourneying Patreon: https://www.patreon.com/c/unjourneying/membership This episode is also sponsored by: SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

Paul talks with biohacking pioneer Dave Asprey about medicalization, microdosing, consciousness, and Dave's new BEYOND Wonderland psychedelics conference in Austin. In this bonus episode, Paul welcomes back Dave Asprey, founder of Bulletproof Coffee and creator of the biohacking movement, to talk about BEYOND Wonderland, the psychedelics conference Dave has revamped for October 12-14 in Austin. They also get into medicalization, the CIA's documented role in psychedelic history, what responsible microdosing regulation could look like, and why Dave is as focused on unlocking latent human ability as he is on fixing what's broken. Want to attend BEYOND Wonderland? Get 10% off your ticket with code THIRDWAVE at wonderlandconference.com (Code expires October 10). Episode links: BEYOND Wonderland – Use code THIRDWAVE for 10% off: https://wonderlandconference.com/ Dave Asprey's website: https://daveasprey.com/ Third Wave occasionally partners with or shares information about other people, companies, and/or providers. While we work hard to only share information about ethical and responsible third parties, we can't and don't control the behavior of, products and services offered by, or the statements made by people, companies, or providers other than Third Wave. Accordingly, we encourage you to research for yourself, and consult a medical, legal, or financial professional before making decisions in those areas. Third Wave isn't responsible for the statements, conduct, services, or products of third parties. We receive a commission from sales arising from customers who use our coupon code. No one is required to use the coupon code. Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.

In this episode of The Psychedelic Podcast, Paul F. Austin speaks with computer scientist, climate investor, and Nexus author Ramez Naam about psychedelics, AI, neurotechnology, and cognitive liberty. Find full show notes and links here: https://thethirdwave.co/podcast/episode-374/?ref=278 Ramez shares how psychedelic experiences sparked his interest in neuroscience, inspired his books, and helped redirect his work toward climate and clean energy. He and Paul explore what brain-computer interfaces can do today, the future of psychedelic mental healthcare, and how to protect freedom of thought as AI becomes a more personal tool. Ramez Naam is a computer scientist, mission-focused investor, climate activist, and award-winning author of science fiction and nonfiction. His Nexus trilogy explores the possibilities of mind-to-mind communication technology, while his nonfiction examines human augmentation, neuroscience, climate, and clean energy. He serves as Co-Chair for Energy and Environment at Singularity University and invests through Planetary VC in companies working on clean energy, climate technology, and beneficial uses of AI. Highlights: How psychedelics inspired Ramez's interest in neuroscience and his five books What today's brain-computer interfaces can and cannot do Psilocybin, 5-MeO-DMT, and the future of mental healthcare Medicalization, decriminalization, and psychedelic access The LSD experience that helped shape Ramez's climate work Clean energy progress and the challenges that remain AI privacy, cognitive liberty, and the freedom to think Episode Links: Ramez Naam's website: rameznaam.com Ramez Naam on X: x.com/ramez Ramez Naam on Instagram: instagram.com/rameznaam Episode Sponsors: SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.